Sandostatin desensitization-a strategy useful for patients with carcinoid tumors, intolerant to sandostatin

Riferimento: 
Cancer Chemother Pharmacol. 2011 Jul;68(1):225-6.
Autori: 
Vinjamaram S1, Iyer R.
Fonte: 
Cancer Chemother Pharmacol. 2011 Jul;68(1):225-6.
Anno: 
2011
Azione: 
Sandostatina a rilascio immediato (IR) è spesso usata per trattare pazienti con tumori carcinoidi, dopo una strategia di desensibilizzazione.
Target: 
Sandostatina (IR)/tumori carcinoidi.

ABSTRACT
Sandostatin immediate release (IR) is frequently used to treat patients with carcinoid tumors. However, some patients are unable to tolerate the immediate side effects of sandostatin IR leading to discontinuation of the drug. There is no literature available to guide the management of patients' sensitivity/intolerance to sandostatin IR. We report a 49-year-old male with carcinoid tumor who was intolerant to sandostatin IR initially but was able to tolerate the drug after we employed a desensitization strategy.